Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin

American Journal of Pathology

Volumn 161, Issue 5, 2002, Pages 1695-1700

  Castellani, Patrizia ^a   Borsi, Laura ^a   Carnemolla, Barbara ^a   Birò, Attila ^a   Dorcaratto, Alessandra ^b   Viale, Giuseppe L ^b   Neri, Dario ^c   Zardi, Luciano ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRONECTIN; KI 67 ANTIGEN; RECOMBINANT ANTIBODY; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ARTICLE; ASTROCYTOMA; CANCER DIAGNOSIS; CANCER GRADING; CELL PROLIFERATION; DIAGNOSTIC TEST; HUMAN; HUMAN TISSUE; IMMUNOSCINTIGRAPHY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

EID: 0036841992     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64446-X     Document Type: Article

References (30)

1. Van Den Hoff A: Stromal involvement in malignant growth. Adv Cancer Res 1988, 50:159-196
2. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1998, 86:353-564
3. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE: Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987, 6:2337-2342
4. Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG: A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors J Cell Biol 1989, 108:1139-1148
5. Castellani P, Viale G, Dorcaratto A, Nicolò G, Kaczmarek J, Querzè G, Zardi L: The fibronectin isoform containing ED-B oncofetal domain: A marker of angiogenesis. Int J Cancer 1994, 59:612-618
6. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D: Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998, 273:21769-21776
7. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, Leprini A, Borsi L, Castellani P, Zardi L, Neri D, Riva P: Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clinical Cancer Res, in press
8. Neri D, Carnemolla B, Nissim A, Balza E, Leprini A, Querzè G, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G: Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nature Biotechnol 1997, 15:1271-1275
9. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, Dinkelborg L, Neri D, Zardi L: A high-affinity human antibody that targets tumoral blood vessels. Blood 1999, 94:192-198
10. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D: Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999, 59:347-353
11. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda Y, Burrone O, Neri D, Zardi L: Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer, in press.
12. Birchler MB, Viti F, Zardi L, Spiess B, Neri D: Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nature Biotechnol 1999, 17:984-988
13. Nilsson F, Kosmehl H, Zardi L, Neri D: Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001, 61:711-716
14. Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L: Enhancement of the antitumor properties of interleukin-2 by its targeted delivery the blood vessels extracellular matrix. Blood 2002, 99:1659-1665
15. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D: Enhancement of the anti-tumor activity of interleukin-12 by targeted delivery to neo-vasculature. Nat Biotechnol 2002, 20:1-7
16. Kleihues P, Cavenee WK (Eds): Pathology and Genetics of Tumours of the Nervous System. WHO Classification. Lyon, IARC Press, 2000
17. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumours of the nervous system. J Neuropathol Exp Neurol 2002, 3:215-225
18. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolò G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L: Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 1999, 154:1345-1352
19. Balza E, Castellani P, Zijlstra A, Neri D, Zardi L, Siri A: Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer 2001, 94:579-585
20. Kleinbaum DG, Kupper LL (Eds): Applied Regression Analysis and Other Multivariable Methods. Boston, Duxbury Press, 1978, pp 414-446
21. Borsi L, Castellani P, Risso AM, Leprini A, Zardi L: Transforming growth factor β regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett 1990, 261:175-178
22. Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L: The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 1995, 270:6243-6245
23. Carnemolla B, Leprini A, Allemanni G, Saginati M, Zardi L: The inclusion of the type-III repeat ED-B in the fibronectin molecules generates conformational modifications that unmask a cryptic sequence. J Biol Chem 1992, 267:24689-24692
24. Kaczmarek J, Castellani P, Nicolò G, Zardi L: Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1994, 58:11-16
25. Hauptmann S, Zardi L, Siri A, Carnemolla B, Borsi L, Castellucci M, Klosterhalfen B, Hartung P, Weis J, Stocker G, Haubeck H, Kirkpatrick CJ: Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoform. Lab Invest 1995, 73:172-182
26. Kosmehl H, Berndt A, Katenkamp D: Molecular variants of fibronectin and laminin: Structure, physiological occurrence and histopathological aspects. Virchows Arch 1996, 429:311-322
27. Karelina TV, Eisen AZ: Interstitial collagenase and the ED-B oncofetal domain of fibronectin are markers of angiogenesis in human skin tumors. Cancer Detect Prev 1998, 22:438-444
28. Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L: Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain Int J Cancer 1996, 68:397-405
29. Melvin F, Witham TF, Flickinger JC, Kondziolka D, Lunsdorf D: Comprehensive assessment of hemorrhage risks and outcomes after stereotactic biopsies. J Neurosurg 2001, 94:545-551
30. Mittler MA, Beverly CW, Stopa EG: Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg 1996, 85:1091-1094